OPTITHERA

TYPE 2 DIABETES

PREDICTING COMPLICATIONS

Type 2 diabetes is the most common form of diabetes, accounting for more than 90% of cases. It usually manifests in adulthood, in people aged 40 and up. Unfortunately, this form of diabetes is also increasingly appearing in younger people, due in part to higher obesity rates.

Type 2 diabetes is generally characterized by:

  • insulin resistance
  • low insulin production

This causes hyperglycemia, a condition in which blood sugar exceeds normal levels.

In the long term, hyperglycemia can lead to certain complications, affecting the kidneys, brain, heart and blood vessels.

Type 1 diabetes, on the other hand, usually occurs in people under the age of 20. It affects less than 10% of people living with diabetes. This form of diabetes is also known as insulin-dependent diabetes or juvenile diabetes.

You are a patient living with type 2 diabetes.

You and your physician are concerned about the risk of complications associated with type 2 diabetes.

An innovative, non-invasive, user-friendly test based on your DNA is now available to predict your risk of developing complications.

COMPLICATIONS RELATED TO TYPE 2 DIABETES
THAT CAN BE DETECTED BY THE TEST.

Kidney complication

Up to 50% of diabetics develop a complication known as nephropathy. This condition can lead to kidney failure and dialysis.

Heart complication

Type 2 diabetes increases the risk of developing heart disease, which can lead to a heart attack.

Cardiovascular complication and stroke

Type 2 diabetes damages blood vessels, which can lead to hypertension, atherosclerosis and stroke.

Type 2 diabetes can also cause other complications such as retinopathy and neuropathy.

 

OPTITHERA

PREDICT TO PREVENT

OPTITHERA specializes in precision medicine as well as the development and clinical application of innovative technology. After many years of intensive research on type 2 diabetes, OPTITHERA developed a unique and effective test to predict the risk of kidney, heart and cerebrovascular complications related to type 2 diabetes.

Using a saliva sample that you can collect at a clinic or at home, OPTITHERA will analyze your genetic profile with the help of artificial intelligence to determine your risk of developing complications related to diabetes. We call this a polygenic risk score.

ABOUT US

PREDICT TO PREVENT

so you can live better with type 2 diabetes—that’s OPTITHERA’s mission.

Our story

OPTITHERA was founded in 2016 by two distinguished professors at the University of Montreal, Pavel Hamet and Johanne Tremblay, and their collaborators. In recent years, OPTITHERA has analyzed data from more than 20,000 type 2 diabetes patients from 20 countries.

Based on these world-class clinical studies and with the help of artificial intelligence, researchers were able to develop a genome test that can inform your physician if you are at risk of developing complications related to type 2 diabetes.

Our team

Pavel Hamet

Founding President and Chief Medical Officer

Pavel Hamet

Founding President and Chief Medical Officer

Johanne Tremblay

Co-founder, Vice-President and Chief Scientific Officer

Johanne Tremblay

Co-founder, Vice-President and Chief Scientific Officer

Martin Godbout

Chief Executive Officer

Martin Godbout

Chief Executive Officer

News

July 6, 2021

Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control

6 July 2021

Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control

December 12, 2019

Innove-Action Conference @CHUM

12 December 2019

Innove-Action Conference @CHUM

November 21, 2019

Polygenic risk: What’s the score?

21 November 2019

Polygenic risk: What’s the score?

November 1, 2019

Polygenic risk scores predict diabetic complications and their response to therapy

1 November 2019

Polygenic risk scores predict diabetic complications and their response to therapy

Frequently Asked Questions

You have questions about the test?

Check out our Frequently Asked Questions section

Contact us

Interested in learning more about the
OPTITHERA test?

Call us at 514 529-3374

or send us an email at
info@optithera.com

2815 Sherbrooke Street East, Suite 240
Montreal, Quebec, Canada  H2K 1H2

Alert me as soon as the Optithera test is available.